Mangoceuticals, Inc. (MGRX) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-69.5%

$0.07

vs $0.23 price

Levered DCF

-$0.29

After debt service

Piotroski score

3 / 9

Weak

Altman Z-score

-6.14

Distress zone

Rating

C+

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
P/E	-0.34×	-0.55×	-0.64×	-34.68×	-3,921.57×
P/B	0.49×	0.34×	7.65×	112.8×	-4,142.34×
P/S	16.34×	7.78×	8.1×	7,748.07×	0×
EV / EBITDA	-0.33×	-0.62×	-0.66×	-34.68×	-3,954.15×
Gross margin	54.9%	61.7%	59.0%	54.3%	0.0%
Operating margin	-4200.5%	-1294.4%	-1260.3%	-22279.7%	0.0%
Net margin	-4526.9%	-1413.6%	-1259.4%	-22352.1%	0.0%
Current ratio	1.74×	0.05×	3.88×	2.67×	0.57×
Debt / equity	0.02×	0.02×	0.17×	0.57×	-2.35×
Interest coverage	-185.05×	-581.9×	0×	-307.68×	-96.8×
Dividend yield	0.0%	16.7%	0.0%	0.0%	0.0%
Payout ratio	0.0%	-9.2%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Return on equity	-135.8%	-62.4%	-1189.1%	-325.4%	105.9%
Return on invested capital	-123.5%	-56.3%	-1020.4%	-206.0%	-77.7%
Return on assets	-128.3%	-56.6%	-876.7%	-199.2%	-78.5%
Free cash flow yield	-78.5%	-101.6%	-118.1%	-2.0%	-0.0%
Earnings yield	-277.0%	-181.8%	-155.5%	-2.9%	-0.0%
Enterprise value	$6.3M	$4.9M	$5.3M	$68.9M	$69.3M
Net debt / EBITDA	0.06×	-0.02×	0.08×	0.17×	-0.95×
Cash conversion cycle (days)	-740	-1,296	-149	-3,006	0